Canada: Federal Court Considers Patent Listing For Combination Drug Products

Justice Hughes Continues Strict Application Of Product Specificity Test
Last Updated: October 21 2014
Article by Eileen McMahon and Albert Chan

The Federal Court recently upheld two rulings of a prothonotary, both regarding listing of patents on the Patent Register under the Patented Medicines (Notice of Compliance) Regulations (PM(NOC) Regulations) against drug products with multiple medicinal ingredients.1 In his ruling, Justice Hughes applied the "product specificity" test for listing patents under the PM(NOC) Regulations. This ruling runs contrary to the current practice and guidance issued by Health Canada. This Federal Court decision is being appealed to the Federal Court of Appeal.


Two generic pharmaceutical manufacturers, Teva Canada Limited (Teva) and Apotex Inc. (Apotex), were involved in PM(NOC) proceedings against ViiV Healthcare ULC (ViiV) relating to two ViiV products: KIVEXA and TRIZIVIR.

The two ViiV products at issue in the appeals are fixed-dose combination products for the treatment of HIV/AIDS. KIVEXA is a co-formulated tablet with two active ingredients, abacavir hemisulfate and lamivudine, while TRIZIVIR is a co-formulated tablet with three active ingredients, abacavir hemisulfate, lamivudine, and zidovudine. ViiV had listed Canadian patent 2,289,753 (the '753 patent) on the Patent Register against both KIVEXA and TRIZIVIR.

The '753 patent contained two claims that were important in the appeal. First, the '753 patent claimed abacavir hemisulfate, in what ViiV characterized as a classic "compound" claim. Second, the '753 patent claimed a combination of abacavir hemisulfate together with one or more medicinal ingredients taken from a class. The patent description named both lamivudine and zidovudine as class members. There was no claim in the '753 patent specifically directed to the two- or three-ingredient combination contained in KIVEXA and TRIZIVIR.

Under section 4(2) of the PM(NOC) Regulations, a patent may be listed for a drug product if it contains a claim to either (a) the medicinal ingredient, (b) the formulation, (c) the dosage form, or (d) the use of a medicinal ingredient, as found in an approved regulatory submission related to that drug product. (In Canada, a regulatory submission is approved by means of a "notice of compliance" or NOC.) ViiV submitted that the '753 patent could be listed against the regulatory submission directed to both the medicinal ingredient and the formulation for KIVEXA and TRIZIVIR, whereas the Minister of Health submitted that the '753 patent could be listed against the regulatory submission for the medicinal ingredient only. Prothonotary Milczynski issued orders in the Teva and Apotex proceedings that the '753 patent could not be listed against regulatory submissions for the medicinal ingredient or formulation for KIVEXA or TRIZIVIR.2

The Ruling on Appeal

Justice Hughes upheld the orders of Prothonotary Milczynski, holding that the '753 patent was not listable against the regulatory submissions for KIVEXA or TRIZIVIR. In doing so, he relied on prior jurisprudence, which established a requirement for "product specificity" between the patent to be listed and the regulatory submission against which the listing was sought.

The "product specificity" jurisprudence

Justice Hughes canvassed earlier decisions by the Federal Court and Federal Court of Appeal, and summarized the jurisprudence relating to listing of patents on the Patent Register as follows:

  • the product specificity requirements are the same across the listing categories under section 4(2) of the PM(NOC) Regulations (i.e., medicinal ingredient, formulation, dosage form and use);
  • there must be "precise and specific matching between what the patent claims and the product/use/dosage forms for which the NOC has been granted" in order for the Minister to properly list the patent on the Patent Register;
  • a claim for a formulation means a claim that includes both medicinal and non-medicinal ingredients, therefore a claim directed to medicinal ingredients only does not qualify for listing against a formulation under section 4(2)(b) of the PM(NOC) Regulations; and
  • where a patent claims only one medicinal ingredient, it cannot be listed against a NOC obtained for two or more medicinal ingredients.3

The '753 patent is not listable

As to the first relevant claim in the '753 patent, Justice Hughes ruled that a patent claiming a single compound may not be listed against a combination product under section 4(2)(a) of the PM(NOC) Regulations. Such a patent did not claim the "medicinal ingredients." Justice Hughes held that each of the medicinal ingredients must be named in the claim in order for the patent to be listed. Justice Hughes also declined to allow listing on policy grounds, stating such policy considerations were better left for higher courts.

Justice Hughes also ruled that a "formulation" claim of one medicinal ingredient in combination with another selected from a class could not be listed against the formulation of a combination drug product, even if the second ingredient is listed as a class member in the patent description. Further, in order to be a proper "formulation" claim, the jurisprudence had established that the patent claim must include both medicinal and non-medicinal ingredients, and at minimum each medicinal ingredient must be named in the claim in order for the patent to be listed.


There is now a significant divergence between the rulings of the courts and the practices of the Minister of Health. Both of the ViiV decisions to date are explicitly contrary to both the PM(NOC) Guidance Document published by Health Canada and the practices of the Office of Patented Medicines and Liaison (OPML), the Health Canada office tasked with administration of the Patent Register. OPML's current practice, as set out in guidance documents published by Health Canada, is to allow listing of patents claiming a single medicinal ingredient against combination products. Further, the Minister of Health represented that its current practice is to consider listing a patent claiming a combination of medicinal ingredients as a "formulation" listing, regardless of whether the patent claim includes non-medicinal ingredients. The Minister of Health made written and oral arguments in favour of patent listing in this case, to no effect on the Court's decision.

Justice Hughes' decision is under appeal. For the time being, it seems that the courts will strictly enforce the "product specificity" listing requirements for both "medicinal ingredient" and "formulation" patent listings.


1 Viiv Healthcare ULC v Teva Canada Limited, 2014 FC 893.

2 Teva was the first to initiate PM(NOC) proceedings, and was the first to have a motion heard and decided, see Viiv Healthcare ULC v Teva Canada Limited, 2014 FC 328. With the consent of ViiV and the Minister of Health, Apotex subsequently made similar motions in two additional PM(NOC) proceedings before Prothonotary Milczynski, proceeding on identical evidence as in the Teva motion and resulting in identical orders. ViiV appealed each order made by Prothonotary Milczynski, and the appeals were consolidated in a single hearing before Justice Hughes on consent of all parties.

3 The summary was based on Abbott Laboratories Ltd v Canada (Attorney General), 2008 FCA 244; GD Searle & Co v Canada (Minister of Health), 2009 FCA 35; Bayer Inc v Canada (Minister of Health), 2009 FC 1171, aff'd 2010 FCA 161; Purdue Pharma Canada v Canada (Attorney General), 2011 FCA 132; and Gilead Sciences Canada Inc v Canada (Minister of Health), 2012 FCA 254.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.